公开(公告)号：US20230212679A1

公开(公告)日：2023-07-06

申请号：US17692698

申请日：2022-03-11

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Taro Semba ,  Yusuke Narita ,  Yukinori Minoshima ,  Atsumi Yamaguchi ,  Yusuke Adachi ,  Kazuhiko Yamada ,  Junji Matsui ,  Tadashi Kadowaki ,  Kentaro Takahashi ,  Yasuhiro Funahashi

IPC: C12Q1/6886 ,  A61K31/47 ,  G01N33/574 ,  A61K31/517 ,  A61K31/404 ,  A61K31/4025

CPC classification number: C12Q1/6886 ,  A61K31/47 ,  A61K31/404 ,  A61K31/517 ,  A61K31/4025 ,  G01N33/574 ,  G01N33/5748 ,  G01N33/57488 ,  G01N33/57496 ,  C12Q2600/16 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2333/82 ,  G01N2333/515 ,  G01N2333/916 ,  G01N2800/52

Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.

公开(公告)号：US11598776B2

公开(公告)日：2023-03-07

申请号：US15934242

申请日：2018-03-23

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Funahashi ,  Tadashi Kadowaki ,  Junji Matsui ,  Jason S. Simon ,  Lucy Xu

IPC: G01N33/53 ,  G01N33/574 ,  C12Q1/6886 ,  A61K31/47

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.

公开(公告)号：US20190000797A1

公开(公告)日：2019-01-03

申请号：US15750712

申请日：2016-08-18

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Kiyoshi Okamoto ,  Junji Matsui ,  Corina Dutcus

IPC: A61K31/357 ,  A61K31/47 ,  A61P35/00 ,  A61K31/664

Abstract: A novel tumor therapeutic agent for a combination therapy is disclosed. More specifically, a tumor therapeutic agent used for a combination therapy of lenvatinib, ifosfamide, and etoposide is disclosed.

公开(公告)号：US20170191137A1

公开(公告)日：2017-07-06

申请号：US15460629

申请日：2017-03-16

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Taro Semba ,  Yusuke Narita ,  Yukinori Minoshima ,  Atsumi Yamaguchi ,  Yusuke Adachi ,  Kazuhiko Yamada ,  Junji Matsui ,  Tadashi Kadowaki ,  Kentaro Takahashi ,  Yasuhiro Funahashi

IPC: C12Q1/68 ,  G01N33/574 ,  A61K31/47

CPC classification number: C12Q1/6886 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/47 ,  A61K31/517 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/574 ,  G01N33/5748 ,  G01N33/57488 ,  G01N33/57496 ,  G01N2333/515 ,  G01N2333/82 ,  G01N2333/916 ,  G01N2800/52

Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.

公开(公告)号：US20170096493A1

公开(公告)日：2017-04-06

申请号：US15382821

申请日：2016-12-19

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yoshimasa Sakamoto ,  Yusuke Adachi ,  Junji Matsui ,  Yu Kato ,  Yoichi Ozawa ,  Takanori Abe ,  Ken Ito ,  Yuya Nakazawa ,  Sho Tachino ,  Katsuhisa Suzuki ,  Kishan Agarwala ,  Kana Hoshino ,  Masahiko Katayama

IPC: C07K16/32 ,  A61K31/337 ,  A61K31/47 ,  A61K39/395 ,  A61K33/24

CPC classification number: C07K16/32 ,  A61K31/337 ,  A61K31/47 ,  A61K33/24 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  C07K14/705 ,  C07K14/71 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/3023 ,  C07K16/303 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/21 ,  C07K2319/42 ,  C12N9/14 ,  C12Y301/03001 ,  A61K2300/00

Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.